Literature DB >> 14696868

Biotechnology and drug discovery: from bench to bedside.

Yoav Avidor1, Nicola J Mabjeesh, Haim Matzkin.   

Abstract

New biotechnology and drug discovery technologies are facilitating the rapid expansion of the clinical drug chest, empowering clinicians with a better understanding of disease as well as novel modalities for treating patients. Important research tools and themes include genomics, proteomics, ligand-receptor interaction, signal transduction, rational drug design, biochips, and microarrays. Emerging drug classes include monoclonal antibodies, cancer vaccines, gene therapy, antisense strands, enzymes, and proteins. In this article, we review these topics and illustrate their potential impact by presenting an overview of promising drugs in the pipeline. Clinicians who use these novel treatments must become familiar with these trends.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696868     DOI: 10.1097/01.SMJ.0000066654.35645.F7

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Clinical comparability and European biosimilar regulations.

Authors:  Huub Schellekens; Ellen Moors
Journal:  Nat Biotechnol       Date:  2010-01       Impact factor: 54.908

2.  Selective tumor cell targeting by the disaccharide moiety of bleomycin.

Authors:  Zhiqiang Yu; Ryan M Schmaltz; Trevor C Bozeman; Rakesh Paul; Michael J Rishel; Krystal S Tsosie; Sidney M Hecht
Journal:  J Am Chem Soc       Date:  2013-02-13       Impact factor: 15.419

3.  Biosimilar therapeutics-what do we need to consider?

Authors:  Huub Schellekens
Journal:  NDT Plus       Date:  2009-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.